Support of TILs cell therapy

Half of this incredible investment in the Brown Cancer Center, $1.5 million, supports the TILs program by providing funding for research staff, supplies and faculty time dedicated to clinical trials. The goal is to increase capacity and access for participants in clinical trials for TILs and other immunotherapies.

The Brown Cancer Center is a lead enrolling center in TILs trials and has had patients travel to Louisville from all over the United States. The success of the program is directly related to the Gibbs Foundation initial investment of $1.5 million in 2022.

This philanthropic investment follows FDA approval of the cell product AMTAGVI (lifileucel), developed by Iovance Biotherapeutics for the treatment of melanoma patients. The Brown Cancer Center participated in these clinical trials leading to this FDA approval and is one of the first authorized treatment centers.

Although the initial FDA approval is specific to metastatic melanoma, the expansion of this cellular therapy to other cancers is being tested at Brown Cancer Center and elsewhere with a goal to obtain FDA approval in several solid tumor types in the future. Read more on the FDA approval in the .

Creation of Gibbs Pancreatic Cancer Research Program

Through $1.5 million over three years, the Gibbs Pancreatic Cancer Research Program will be created at the University of Louisville to support efforts in testing novel therapeutic agents for the treatment of pancreatic cancer. Five $50,000 pilot grants will be awarded to researchers each year for the development of novel therapeutics to treat pancreatic cancer and increase clinical trials dedicated to treating pancreatic cancer. This center will also provide funding for trial research staff and faculty time dedicated to these projects.

“The Gibbs Foundation is thrilled to be continuing our partnership with the Brown Cancer Center and the fight against cancer. Based on the positive outcomes of so many patients who have been through the TILs program, it is a battle we are winning,” said executive director of the Gibbs Foundation Hannah Roquet. “The creation of the Gibbs Pancreatic Cancer Research Program is especially meaningful as it continues the legacy of our founder, George Gibbs, who fought his own battle valiantly, and provides the opportunity for groundbreaking research in a cancer that has taken the lives of many too quickly and without warning.  We are looking forward to the future of this very special program.”

The Gibbs Foundation, Inc. was established in 2014 by George Gibbs of Louisville who died in 2022 of pancreatic cancer at age 87. The Gibbs Foundation previously supported health research at UofL through gifts of more than $2.5 million to create and expand the Gibbs Lung Research Program.

“The Brown Cancer Center has one goal – to end cancer,” said Jason Chesney, chief administrative officer and director of the Brown Cancer Center, who also serves as chief of the Division of Medical Oncology and Hematology at the UofL School of Medicine. “As more cancer centers across the country begin to implement TILs programs, we will be saving more lives. Through the philanthropy of the Gibbs Foundation, we continue to be one step closer to achieving this goal. Their dedication to finding a cure and increasing access to novel therapeutics is astounding.”

More information on TILs therapy and UofL Health – Brown Cancer Center is available at .

The Gibbs Foundation Inc. is giving $1.5 million to the University of Louisville over three years to fund additional research staff and faculty time dedicated to clinical trials, increasing capacity for trial participants in the tumor infiltrating lymphocytes program, or TILs.

“We are so very grateful to the Gibbs Foundation for this gift. By allowing the Brown Cancer Center to expand this clinical trial and treat more patients with this innovative therapy, it provides hope for more families who are battling cancer and advances these therapies, potentially benefitting even more cancer patients and families,” said Lori Gonzalez, UofL’s interim president.

In clinical trials at the , therapy known as tumor infiltrating lymphocytes, or TILs, has been shown to be effective in treating advanced melanoma patients, for whom the median survival is only eight months. TILs treatment involves removing one of a patient’s own tumors, preserving, activating and expanding immune cells from the tumor, then administering these immune cells into the patient. As a result of its success in melanoma patients, BCC is expanding the TILs program to test the therapy for the treatment of other cancers.

TILs patients face a long wait time due to the complex and time-consuming nature of the therapy and demands on clinical research staff. The gift from the Gibbs Foundation will allow UofL to hire additional nurses and coordinators and dedicate more of the oncologists’ research time to support TILs, a complex inpatient procedure. The gift is expected to result in the treatment of at least 25 additional patients.

“The Gibbs Foundation Board of Directors has been dramatically impressed with the success of the Brown Cancer Center’s immunotherapy work conceived and spearheaded by Dr. Jason Chesney.  We look forward to continuing the vision of our founder George Gibbs in helping to facilitate this great effort,” said Ivan J. Schell, Gibbs Foundation board member. “The Gibbs Foundation supports the BCC and its dedicated team of physicians as they gain ground in the search for a cure for all cancers.”  

The Gibbs Foundation Inc. was established in 2014 by George and Betty Gibbs of Louisville. George died in January of pancreatic cancer at age 87. The Gibbs Foundation currently also supports lung health research at UofL through gifts of more than $2.5 million to create and expand the lung research program.

Cancer remains one of the most difficult and deadly challenges in health care, killing more than 600,000 people each year in the U.S. and nearly 10 million worldwide. Kentuckians are affected at a higher rate than residents of any other state. BCC serves more than 26,000 cancer patients every year and has the largest early-phase cancer trials program in the region. BCC is a global leader in the clinical testing of new immunotherapies, treatments that activate the body’s immune system to fight cancer and is an early adopter of these treatments.

“My goal is to help make cancer something that people one day study in history classes instead of medical schools, and I truly believe we are getting closer to that day,” said Jason Chesney, chief of the UofL Division of Medical Oncology and Hematology and director of the Brown Cancer Center. “This gift allows us to increase the number of patients and advance this lifesaving technology.”